A review of opioid overdose prevention and naloxone prescribing: Implications for translating community programming into clinical practice

Substance Abuse

Volumn 36, Issue 2, 2015, Pages 240-253

  Mueller, Shane R ^a,d   Walley, Alexander Y ^b   Calcaterra, Susan L ^a,c   Glanz, Jason M ^d,e   Binswanger, Ingrid A ^a,c,d  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DENVER HEALTH MEDICAL CENTER   (United States)

^d KAISER PERMANENTE   (United States)

^e Food Science and Human Nutrition   (United States)

Author keywords

opioids; overdose; Prevention; primary care

Indexed keywords

NALOXONE; NARCOTIC ANALGESIC AGENT;

COMMUNITY CARE; DRUG OVERDOSE; GENERAL PRACTICE; HEALTH CARE DELIVERY; HUMAN; PATIENT EDUCATION; PROCEDURES;

ANALGESICS, OPIOID; COMMUNITY HEALTH SERVICES; DRUG OVERDOSE; GENERAL PRACTICE; HEALTH SERVICES ACCESSIBILITY; HUMANS; NALOXONE; PATIENT EDUCATION AS TOPIC;

EID: 84931572910     PISSN: 08897077     EISSN: 15470164     Source Type: Journal    
DOI: 10.1080/08897077.2015.1010032     Document Type: Review

References (101)

1. Paulozzi LJ. Drug-induced deaths-United States, 2003-2007. MMWR Surveill Summ. 2011;60(Suppl): 60-61.
2. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010;363:1981-1985.
3. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15:618-627.
4. Centers for Disease Control and Prevention. Vital signs: risk for overdose frommethadone used for pain relief-United States, 1999-2010. MMWR Morb Mortal Wkly Rep. 2012;61:493-497.
5. Calcaterra S, Glanz J, Binswanger IA. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999-2009. Drug Alcohol Depend. 2013;131:263-270.
6. Warner M, Chen LH, Makuc DM, Anderson RN, Miniño AM. Drug Poisoning Deaths in the United States, 1980-2008. Hyattsville, MD: National Center for Health Statistics; 2011.
7. Jones C, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309:657-659.
8. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008.MMWR Morb Mortal Wkly Rep. 2011;60:1487-1492.
9. Campana M.Overdosemortality and naloxone distribution in Italy. Paper presented at Preventing Heroin Overdose: Pragmatic Approaches; January 13-14, 2000; Seattle, W.A.
10. Darke S, Hall W. The distribution of naloxone to heroin users. Addiction. 1997;92:1195-1199.
11. Community-based opioid overdose prevention programs providing naloxone-United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61:101-105.
12. Throckmorton DC, Compton WM, Lurie P. Management of opioid analgesic overdose. N Engl J Med. 2012;367:1371; author reply 1372-1373.
13. Substance Abuse and Mental Health Services Administration. SAMHSA Opioid Overdose Prevention Toolkit. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014. HHS Publication No. (SMA) 13-4742.
14. Matheson C, Pflanz-Sinclair C, Aucott L, et al. Reducing drug related deaths: a pre-implementation assessment of knowledge, barriers and enablers for naloxone distribution through general practice. BMC Fam Pract. 2014;15:12.
15. Hansen A. Norway tries naloxone in spray form to prevent deaths from drug overdose. BMJ. 2014;348:g1686.
16. Hakansson A, Vedin A, Wallin C, Ah K. [Distribution of naloxone to prevent death from heroin overdose. Study of opioid dependent patients' attitudes to be part of the antidote program]. Lakartidningen. 2013;110:1340-1342.
17. Strang J, Kelleher M, Best D, Mayet S, Manning V. Emergency naloxone for heroin overdose. BMJ. 2006;333:614-615.
18. Dettmer K, Saunders B, Strang J. Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ. 2001;322:895-896.
19. Seal KH, DowningM, Kral AH, et al. Attitudes about prescribing takehome naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay area. J Urban Health. 2003;80:291-301.
20. Tzemis D, Al-Qutub D, Amlani A, Kesselring S, Buxton JA. A quantitative and qualitative evaluation of the british columbia take home naloxone program. CMAJ Open. 2014;2:E153-E161.
21. Lenton S, Dietze P, Olsen A, Wiggins N, McDonald D, Fowlie C. Working together: expanding the availability of naloxone for peer administration to prevent opioid overdose deaths in the Australian capital territory and beyond. Drug Alcohol Rev. October 1 2014 [Epub ahead of print].
22. Liberati A, Altman DG, Tetzlaff J, et al. The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65-W94.
23. Galea S, Worthington N, Piper TM, Nandi VV, Curtis M, Rosenthal DM. Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City. Addict Behav. 2006;31:907-912.
24. Strang J, Manning V, Mayet S, et al. Overdose training and takehome naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Addiction. 2008;103:1648-1657.
25. Gaston RL, Best D, Manning V, Day E. Can we prevent drug related deaths by training opioid users to recognise and manage overdoses? Harm Reduct J. 2009;6:26.
26. Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. J Urban Health. 2011;88:1020-1030.
27. Bennett T, Holloway K. The impact of take-home naloxone distribution and training on opiate overdose knowledge and response: an evaluation of the thn project in Wales. Drugs Educ Prev Policy. 2012;19:320-328.
28. Doe-Simkins M, Walley AY, Epstein A, Moyer P. Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health. 2009;99:788-791.
29. Enteen L, Bauer J, McLean R, et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health. 2010;87:931-941.
30. Heller DI, Stancliff S. Providing naloxone to substance users for secondary administration to reduce overdose mortality in New York City. Public Health Rep. 2007;122:393-397.
31. Lankenau SE, Wagner KD, Silva K, et al. Injection drug users trained by overdose prevention programs: responses to witnessed overdoses. J Community Health. 2013;38:133-141.
32. Leece PN, Hopkins S, Marshall C, Orkin A, Gassanov MA, Shahin RM. Development and implementation of an opioid overdose prevention and response program in Toronto, Ontario. Can J Public Health. 2013;104:e200-e204.
33. Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J Addict Dis. 2006;25:89-96.
34. Piper TM, Rudenstine S, Stancliff S, et al. Overdose prevention for injection drug users: lessons learned from naloxone training and distribution programs in New York City. Harm Reduct J. 2007;4:3.
35. Seal KH, Thawley R, Gee L, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health. 2005;82:303-311.
36. Yokell MA, Green TC, Bowman S, McKenzie M, Rich JD. Opioid overdose prevention and naloxone distribution in Rhode Island. Med Health R I. 2011;94:240-242.
37. Walley AY, Doe-Simkins M, Quinn E, Pierce C, Xuan Z, Ozonoff A. Opioid overdose prevention with intranasal naloxone among people who take methadone. J Subst Abuse Treat. 2013;44:241-247.
38. Albert S, BrasonFW2nd, SanfordCK, DasguptaN, Graham J, Lovette B. Project Lazarus: community-based overdose prevention in rural North Carolina. Pain Med. 2011;12(Suppl 2):S77-S85.
39. McAuley A, Lindsay G, Woods M, Louttit D. Responsible management and use of a personal take-home naloxone supply: a pilot project. Drugs. 2010;17:388-399.
40. Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.
41. Kerr D, Dietze P, Kelly AM, Jolley D. Attitudes of Australian heroin users to peer distribution of naloxone for heroin overdose: perspectives on intranasal administration. J Urban Health. 2008;85:352-360.
42. Wakeman SE, Bowman SE, McKenzie M, Jeronimo A, Rich JD. Preventing death among the recently incarcerated: an argument for naloxone prescription before release. J Addict Dis. 2009;28: 124-129.
43. Lagu T, Anderson BJ, Stein M. Overdoses among friends: drug users are willing to administer naloxone to others. J Subst Abuse Treat. 2006;30:129-133.
44. Strang J, Powis B, Best D, et al. Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction. 1999;94:199-204.
45. Baca CT, Grant KJ.What heroin users tell us about overdose. J Addict Dis. 2007;26:63-68.
46. Piper TM, Stancliff S, Rudenstine S, et al. Evaluation of a naloxone distribution and administration program in New York City. Subst Use Misuse. 2008;43:858-870.
47. Tobin KE, Gaasch WR, Clarke C, MacKenzie E, Latkin CA. Attitudes of emergencymedical service providers towards naloxone distribution programs. J Urban Health. 2005;82:296-302.
48. Wagner KD, Valente TW, Casanova M, et al. Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. Int J Drug Policy. 2010;21:186-193.
49. Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. Addiction. 2008;103:979-989.
50. Kim D, Irwin KS, Khoshnood K. Expanded access to naloxone: options for critical response to the epidemic of opioid overdosemortality. Am J Public Health. 2009;99:402-407.
51. Sherman SG, Gann DS, Tobin KE, Latkin CA, Welsh C, Bielenson P. "The life they save may be mine": diffusion of overdose prevention information from a city sponsored programme. Int J Drug Policy. 2009;20:137-142.
52. Sherman SG, Gann DS, Scott G, Carlberg S, Bigg D, Heimer R. A qualitative study of overdose responses among Chicago IDUs. Harm Reduct J. 2008;5:2.
53. Tobin KE, Sherman SG, Beilenson P, Welsh C, Latkin CA. Evaluation of the staying alive programme: training injection drug users to properly administer naloxone and save lives. Int J Drug Policy. 2009;20:131-136.
54. Beletsky L, Ruthazer R, Macalino GE, Rich JD, Tan L, Burris S. Physicians' knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities. J Urban Health. 2007;84:126-136.
55. Coffin PO, Fuller C, Vadnai L, Blaney S, Galea S, Vlahov D. Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City. J Urban Health. 2003;80:288-290.
56. Green TC, Bowman SE, Zaller ND, Ray M, Case P, Heimer R. Barriers to medical provider support for prescription naloxone as overdose antidote for lay responders. Subst Use Misuse. 2013;48: 558-567.
57. Loimer N, Hofmann P, Chaudhry HR. Nasal administration of naloxone is as effective as the intravenous route in opiate addicts. Int J Addict. 1994;29:819-827.
58. Leavitt SB. Intranasal naloxone for at-home opioid rescue. Pract Pain Manag. 2010;46.
59. Kelly AM, Kerr D, Dietze P, Patrick I, Walker T, Koutsogiannis Z. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust. 2005;182:24-27.
60. Kerr D, Dietze P, Kelly AM. Intranasal naloxone for the treatment of suspected heroin overdose. Addiction. 2008;103:379-386.
61. Wermeling DP. Opioid harm reduction strategies: focus on expanded access to intranasal naloxone. Pharmacotherapy. 2010;30:627-631.
62. Barton ED, Colwell CB, Wolfe T, et al. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J EmergMed. 2005;29:265-271.
63. Buajordet I, Naess AC, Jacobsen D, Brors O. Adverse events after naloxone treatment of episodes of suspected acute opioid overdose. Eur J Emerg Med. 2004;11:19-23.
64. Kerr D, Kelly AM, Dietze P, Jolley D, Barger B. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction. 2009;104:2067-2074.
65. Merlin MA, Saybolt M, Kapitanyan R, et al. Intranasal naloxone delivery is an alternative to intravenous naloxone for opioid overdoses. Am J Emerg Med. Mar 2010;28:296-303.
66. Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann InternMed. 2013;158:1-9.
67. Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal in Russian cities. J Med Econ. 2013;16:1051-1060.
68. Advisory Council on the Misuse of Drugs. Consideration of Naloxone. London: Advisory Council on the Misuse of Drugs; 2012.
69. Burris S, Beletsky L, Castagna C, Coyle C, Crowe C, McLaughlin J. Stopping an invisible epidemic: legal issues in the provision of naloxone to prevent opioid overdose. Drexel Law Rev. 2009;1:273-339.
70. Davis C, Chang S. Legal Interventions to Reduce Overdose Mortality: Naloxone Access and Overdose Good Samaritan Laws. The Network for Public Health Law, RobertWood Johnson Foundation; 2014. Available at: https://www.networkforphl.org/asset/qz5pvn/networknaloxone-10-4.pdf
71. Davis C, Webb D, Burris S. Changing law from barrier to facilitator of opioid overdose prevention. J Law Med Ethics. 2013;41(Suppl 1):33-36.
72. Bazazi AR, Zaller ND, Fu JJ, Rich JD. Preventing opiate overdose deaths: examining objections to take-home naloxone. J Health Care Poor Underserved. 2010;21:1108-1113.
73. Dasgupta N, Sanford C, Albert S, Brason FW II. Opioid drug overdoses: a prescription for harm and potential for prevention. Am J Lifestyle Med. 2010;4:32-37.
74. Wright N, Oldham N, Francis K, Jones L. Homeless drug users' awareness and risk perception of peer "take home naloxone" use-a qualitative study. Subst Abuse Treat Prev Policy. 2006;1:28.
75. American Medical Association. D-95.987 Prevention of Opiod Overdose.Available at: https://www.ama-assn.org/ssl3/ecomm/Policy FinderForm.pl?site=www.ama-assn.org&uri=/resources/html/Policy Finder/policyfiles/DIR/D-95.987.HTM
76. Green TC, Zaller N, Rich J, Bowman S, Friedmann P. Revisiting Paulozzi et al.'s "Prescription drug monitoring programs and death rates from drug overdose". Pain Med. 2011;12:982-985.
77. US Food and Drug Administration. Guidance for industry-format and content of proposed risk evaluation and mitigation strategies (REMS), REMS assessments, and proposed REMS modifications. 2009. Available at: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM184128.pdf
78. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of oxycontin. N Engl J Med. 2012;367:187-189.
79. Knopf A. Naloxone auto-injector gains fda approval. Behav Healthc. 2014;34:48-49.
80. Beletsky L, Rich JD, Walley AY. Prevention of fatal opioid overdose. JAMA. 2012;308:1863-1864.
81. George S, Moreira K. A guide for clinicians on "take home" naloxone prescribing. Addict Disord Their Treat. 2008;7:163-167.
82. Worthington N, Markham Piper T, Galea S, RosenthalD.Opiate users' knowledge about overdose prevention and naloxone in NewYork City: a focus group study. Harm Reduct J. 2006;3:19.
83. Substance Abuse and Mental Health Services AdministrationOffice of Applied Studies. Drug Abuse Warning Network, 2003: Area Profiles of Drug-Related Mortality. Rockville, MD: United States Department of Health and Human Services; 2005.
84. Coffin PO, Tracy M, Bucciarelli A, Ompad D, Vlahov D, Galea S. Identifying injection drug users at risk of nonfatal overdose. Acad Emerg Med. 2007;14:616-623.
85. Darke S, Hall W. Heroin overdose: research and evidence-based intervention. J Urban Health. 2003;80:189-200.
86. Sporer KA. Acute heroin overdose. Ann Intern Med. 1999; 130:584-590.
87. Darke S, Mills KL, Ross J, Teesson M. Rates and correlates of mortality amongst heroin users: findings from the Australian Treatment Outcome Study (ATOS), 2001-2009. Drug Alcohol Depend. 2011;115:190-195.
88. Bohnert AS, Tracy M, Galea S. Characteristics of drug users who witness many overdoses: implications for overdose prevention. Drug Alcohol Depend. 2012;120:168-173.
89. Strang J, McCambridge J, Best D, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ. 2003;326:959-960.
90. Binswanger IA, Stern MF, Deyo RA, et al. Release from prison-a high risk of death for former inmates. N Engl J Med. 2007; 356:157-165.
91. Binswanger IA, Nowels C, Corsi KF, et al. Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract. 2012;7:3.
92. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305:1315-1321.
93. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152:85-92.
94. Evans JL, Tsui JI, Hahn JA, Davidson PJ, Lum PJ, Page K. Mortality among young injection drug users in San Francisco: a 10-year followup of the UFO study. Am J Epidemiol. 2012;175:302-308.
95. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300:2613-2620.
96. Green TC, Grau LE, Carver HW, Kinzly M, Heimer R. Epidemiologic trends and geographic patterns of fatal opioid intoxications in Connecticut, USA: 1997-2007. Drug Alcohol Depend. 2011;115:221-228.
97. Warner-Smith M, Darke S, Lynskey M, Hall W. Heroin overdose: causes and consequences. Addiction. 2001;96:1113-1125.
98. Toblin RL, Paulozzi LJ, Logan JE, Hall AJ, Kaplan JA. Mental illness and psychotropic drug use among prescription drug overdose deaths: a medical examiner chart review. J Clin Psychiatry. 2010;71:491-496.
99. Darke S, Sims J, McDonald S, Wickes W. Cognitive impairment among methadone maintenance patients. Addiction. 2000;95:687-695.
100. Havens JR, Oser CB, Knudsen HK, et al. Individual and network factors associated with non-fatal overdose among rural Appalachian drug users. Drug Alcohol Depend. 2011;115:107-112.
101. Chan GM, Stajic M, Marker EK, Hoffman RS, Nelson LS. Testing positive for methadone and either a tricyclic antidepressant or a benzodiazepine is associated with an accidental overdose death: analysis of medical examiner data. Acad Emerg Med. 2006;13:543-547.